HIV Pipeline
← Earnings Calls
01
02
03
04 05 06
Tone
A1 A2 A3
GILD
FY2026 Q1
Raised
Gilead Sciences, Inc. earnings call
Buzzberg read
HIV franchise positioned for durable growth with seven potential launches by 2033
Gilead reported a strong Q1 2026, led by HIV and its new PrEP drug Yes2Go, whose full-year sales guidance was raised to $1 billion. Management also provided an update on its recently closed Arcelix acquisition (anito-cel) and the pending Tubulis ADC deal, emphasizing a robust pipeline and the ability to absorb the heavy acquisition costs. Total product sales: $6.9B (+5% YoY), with HIV franchise at $5.0B (+10% YoY).
Buzzberg read HIV franchise positioned for durable growth with seven potential launches by 2033 Gilead reported a strong Q1 2026, led by HIV and its new PrEP drug Yes2Go, whose full-year sales guidance was raised to $1 billion. Management also provided an update on its recently closed Arcelix acquisition (anito-cel) and the pending Tubulis ADC deal, emphasizing a robust pipeline and the ability to absorb the heavy acquisition costs. Total product sales: $6.9B (+5% YoY), with HIV franchise at $5.0B (+10% YoY). Read full analysisCollapse analysis
Gilead reported a strong Q1 2026, led by HIV and its new PrEP drug Yes2Go, whose full-year sales guidance was raised to $1 billion. Management also provided an update on its recently closed Arcelix acquisition (anito-cel) and the pending Tubulis ADC deal, emphasizing a robust pipeline and the ability to absorb the heavy acquisition costs. Total product sales: $6.9B (+5% YoY), with HIV franchise at $5.0B (+10% YoY).
- Yes2Go sales: $166M in Q1 (up 72% sequential), full-year 2026 guidance raised to $1B from $800M.
- 2026 total product sales guidance raised by $400M to $30.0-30.4B; non-GAAP EPS is a loss of $1.05-$0.65 due to ~$11.5B in acquired IPR&D charges.
- Acquisition of Arcelix closed April 28th; anito-cel PDUFA is December 2026, with revenue expected to begin early 2027.
HIV Revenue$5BReported
Revenue$6.96B-12% QoQ
YES2GO Revenue166Reported
EPS$2.03+9% QoQ
6 grounded callouts
What matters now
The highest-signal changes from the call.
Demand
Yes2Go guidance raised to blockbuster $1 billion in first full year
HIV Treatment
BicLen FDA decision expected in August under priority review
Show 3 more callouts
Oncology
Trodelvy first-line metastatic TNBC decisions expected in second half 2026
Cell Therapy
AnitoCell revenue expected to begin in early 2027
Cell Therapy
AnitoCell positioned as foundational multiple myeloma therapy
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| HIV Revenue | $5B | Reported |
| Revenue | $6.96B | -12% QoQ |
| YES2GO Revenue | 166 | Reported |
| EPS | $2.03 | +9% QoQ |
| Gross margin | 79.24% | Reported |
| Operating margin | 37.16% | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $-1.05–$-0.65In line with consensus | $-0.85 | Maintained |
| RevenueHIV | FY2026 | $1BAbove consensus | $1B | Raised |
| Revenue | FY2026 | $30B–$30.4BIn line with consensus | $30.2B | Raised |
AI, capex & demand read
Management read
Confident
Management repeatedly highlighted execution strength, raised product sales guidance, and framed upcoming decisions and launches as growth catalysts.
all 3 named companies below
Companiesreturns since call
Partners
Partners
Dietmar Berger
Gilead's pending acquisition of Oral Medicines includes a licensing deal with Galapagos for gamgertamig, highlighting a deepening partnership.
Evidence
“we expect to develop in collaboration with Galapagos”
Partners
Dietmar Berger
Gilead is shifting its commercial strategy in HIV treatment by actively marketing a new brand (BicLen) that will cannibalize its flagship Biktarvy, aiming to capture patients who would otherwise switch to competitors. — This is a defensive launch to protect market share; while it may cannibalize Biktarvy, it is expected to keep higher-value patients within Gilead's portfolio.
Evidence
“we continue to target updates from the Phase 3 Island 1 and 2 trials in collaboration with Merck later this quarter.”
Investees
ARCLX
Investees
Daniel O'Day
The completed acquisition is expected to be a major growth driver for Gilead's cell therapy business, with the anito-cel CAR-T targeted for a late-December PDUFA.
Evidence
“Our acquisition of Arcelix, which closed on April 28th, reflects our conviction in the potential of a needle cell as a differentiated option for patients with multiple myeloma.”
External signals
Supply-chain alpha · 3returns since call
The $1 billion full-year 2026 Yes2Go sales target implies a doubling from the current annualized run rate (Q1: $166M, up 72% sequentially) and likely assumes a very high persistency rate, a key risk if real-world adherence is lower than expected.
Evidence
“Given the outperformance of Yes2Go in the first quarter and our growing confidence in the trends we're seeing, we're increasing our 2026 Yes2Go guidance to $1 billion, potentially achieving blockbuster status in its first full year.”
Gilead is shifting its commercial strategy in HIV treatment by actively marketing a new brand (BicLen) that will cannibalize its flagship Biktarvy, aiming to capture patients who would otherwise switch to competitors.
Evidence
“We believe with Biclen, there's an opportunity to play in that switch market, which we haven't had in the past, and move them from Bicarbine, if they're going to switch anyway, to Biclen.”
The company is investing heavily in direct-to-consumer marketing for Yes2Go, which is a significant shift in strategy for a disease where outdated stigma has historically been a barrier to PrEP adoption.
Evidence
“Our DTC started late February, and what we've been seeing is a huge increase in brand awareness and visibility”
Methodology & coverage
Management-only analysis. All 3 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.